Mar. 27 at 10:56 PM
$BRTX DD Cash upfront Licensing agreements: 💰
Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in '24-'25 Phase 2 & Phase 3. (( BEFORE being an FDA approved drug ! ))
🔑 Big Pharma's 3 Major GLP-1 Licensing Deals 12 Months.
Surge in demand for obesity treatments has led "Big Pharma" 💰 paying very significant premiums for early-stage Phase 2 & next-generation candidates FDA phase 2 and phase 3 trials. 🔑
Dec 2025 YaoPharma To
$PFE 💰
$150 Million
$2.09 Billion Total Phase 1 oral small-molecule GLP-1.✅️
May '24Jiangsu Hengrui ToHercules 💰
$110 Million
$6.00 Billion+ Portfolio of GLP-1R agonists for global markets.✅️
Nov 2024 Gilead Sciences To Merck
$MSD 💰
$125 Million*
$1.80 Billion+ GLP-1/GIP co-agonist for metabolic health✅️ .
👍 *Estimated based on industry benchmarks for mid-stage out-licensing of GLP-1 assets in 2024-2025.
Date Licensor (Seller) Licensee (Buyer) Upfront Cash Total Deal Value Target 👍
✅️ Bullish on LOI for
$150 million dollars cash upfront from 1 of 3 Big Pharma's that Require the 3 patents. Also New knowledge in presentation at ORS meeting by
$BRTX on 3-28 is key to partnership leading to Billion dollar drug after FDA approval . ✅️
